☰

Nigel Greig - Publications

Affiliations: 
Drug Design and Development National Institute of Aging, Cabanatuan City, Central Luzon, Philippines 
Tree Info Grants Similar researchers Related pubs Distance to... Nearest Nobel PubMed Report error

46 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Yu SJ, Wang Y, Shen H, Bae EK, Li Y, Sambamurti K, Tones MA, Zaleska MM, Hoffer BJ, Greig NH. DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson's disease. Geroscience. PMID 38563864 DOI: 10.1007/s11357-024-01116-0  0.322
2023 Glotfelty EJ, Tovar-Y-Romo LB, Hsueh SC, Tweedie D, Li Y, Harvey BK, Hoffer BJ, Karlsson TE, Olson L, Greig NH. The RhoA-ROCK1/ROCK2 Pathway Exacerbates Inflammatory Signaling in Immortalized and Primary Microglia. Cells. 12. PMID 37408199 DOI: 10.3390/cells12101367  0.719
2023 Glotfelty EJ, Hsueh SC, Claybourne Q, Bedolla A, Kopp KO, Wallace T, Zheng B, Luo Y, Karlsson TE, McDevitt RA, Olson L, Greig NH. Microglial Nogo delays recovery following traumatic brain injury in mice. Glia. PMID 37401784 DOI: 10.1002/glia.24436  0.734
2023 Kopp KO, Greer ME, Glotfelty EJ, Hsueh SC, Tweedie D, Kim DS, Reale M, Vargesson N, Greig NH. A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders. Biomolecules. 13. PMID 37238617 DOI: 10.3390/biom13050747  0.719
2023 Kuo TT, Chen YH, Wang V, Huang EY, Ma KH, Greig NH, Jung J, Choi HI, Olson L, Hoffer BJ, Tseng KY. PT320, a Sustained-Release GLP-1 Receptor Agonist, Ameliorates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease. International Journal of Molecular Sciences. 24. PMID 36902115 DOI: 10.3390/ijms24054687  0.422
2022 Kopp KO, Glotfelty EJ, Li Y, Greig NH. Glucagon-like Peptide-1 (GLP-1) Receptor Agonists and Neuroinflammation: Implications for Neurodegenerative Disease Treatment. Pharmacological Research. 106550. PMID 36372278 DOI: 10.1016/j.phrs.2022.106550  0.739
2022 Hsueh SC, Scerba MT, Tweedie D, Lecca D, Kim DS, Baig AM, Kim YK, Hwang I, Kim S, Selman WR, Hoffer BJ, Greig NH. Activity of a Novel Anti-Inflammatory Agent F-3,6'-dithiopomalidomide as a Treatment for Traumatic Brain Injury. Biomedicines. 10. PMID 36289711 DOI: 10.3390/biomedicines10102449  0.312
2022 Lecca D, Jung YJ, Scerba MT, Hwang I, Kim YK, Kim S, Modrow S, Tweedie D, Hsueh SC, Liu D, Luo W, Glotfelty E, Li Y, Wang JY, Luo Y, ... ... Greig NH, et al. Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 35234334 DOI: 10.1002/alz.12610  0.691
2021 Li Y, Glotfelty EJ, Karlsson T, Fortuno LV, Harvey BK, Greig NH. The metabolite GLP-1 (9-36) is neuroprotective and anti-inflammatory in cellular models of neurodegeneration. Journal of Neurochemistry. PMID 34569615 DOI: 10.1111/jnc.15521  0.725
2021 Hsueh SC, Luo W, Tweedie D, Kim DS, Kim YK, Hwang I, Gil JE, Han BS, Chiang YH, Selman W, Hoffer BJ, Greig NH. -Adamantyl Phthalimidine: A New Thalidomide-like Drug That Lacks Cereblon Binding and Mitigates Neuronal and Synaptic Loss, Neuroinflammation, and Behavioral Deficits in Traumatic Brain Injury and LPS Challenge. Acs Pharmacology & Translational Science. 4: 980-1000. PMID 33860215 DOI: 10.1021/acsptsci.1c00042  0.31
2021 Wang V, Kuo TT, Huang EY, Ma KH, Chou YC, Fu ZY, Lai LW, Jung J, Choi HI, Choi DS, Li Y, Olson L, Greig NH, Hoffer BJ, Chen YH. Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson's Disease. Acs Pharmacology & Translational Science. 4: 858-869. PMID 33860208 DOI: 10.1021/acsptsci.1c00013  0.463
2020 Yu SJ, Chen S, Yang YY, Glotfelty EJ, Jung J, Kim HK, Choi HI, Choi DS, Hoffer BJ, Greig NH, Wang Y. PT320, Sustained-Release Exendin-4, Mitigates L-DOPA-Induced Dyskinesia in a Rat 6-Hydroxydopamine Model of Parkinson's Disease. Frontiers in Neuroscience. 14: 785. PMID 32848559 DOI: 10.3389/Fnins.2020.00785  0.714
2020 Glotfelty EJ, Olson L, Karlsson TE, Li Y, Greig NH. Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease. Expert Opinion On Investigational Drugs. 1-8. PMID 32412796 DOI: 10.1080/13543784.2020.1764534  0.732
2019 Bader M, Li Y, Tweedie D, Shlobin NA, Bernstein A, Rubovitch V, Tovar-Y-Romo LB, DiMarchi RD, Hoffer BJ, Greig NH, Pick CG. Neuroprotective Effects and Treatment Potential of Incretin Mimetics in a Murine Model of Mild Traumatic Brain Injury. Frontiers in Cell and Developmental Biology. 7: 356. PMID 31998717 DOI: 10.3389/Fcell.2019.00356  0.374
2019 Greig NH, Lecca D, Hsueh SC, Nogueras-Ortiz C, Kapogiannis D, Tweedie D, Glotfelty EJ, Becker RE, Chiang YH, Hoffer BJ. (-)-Phenserine tartrate (PhenT) as a treatment for traumatic brain injury. Cns Neuroscience & Therapeutics. PMID 31828969 DOI: 10.1111/Cns.13274  0.714
2019 Li Y, Glotfelty EJ, Namdar I, Tweedie D, Olson L, Hoffer BJ, DiMarchi RD, Pick CG, Greig NH. Neurotrophic and neuroprotective effects of a monomeric GLP-1/GIP/Gcg receptor triagonist in cellular and rodent models of mild traumatic brain injury. Experimental Neurology. 113113. PMID 31730763 DOI: 10.1016/J.Expneurol.2019.113113  0.748
2019 Glotfelty EJ, Delgado T, Tovar-Y-Romo LB, Luo Y, Hoffer B, Olson L, Karlsson T, Mattson MP, Harvey B, Tweedie D, Li Y, Greig NH. Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury. Acs Pharmacology & Translational Science. 2: 66-91. PMID 31396586 DOI: 10.1021/acsptsci.9b00003  0.754
2019 Hsueh SC, Lecca D, Greig NH, Wang JY, Selman W, Hoffer BJ, Miller JP, Chiang YH. (-)-Phenserine Ameliorates Contusion Volume, Neuroinflammation, and Behavioral Impairments Induced by Traumatic Brain Injury in Mice. Cell Transplantation. 963689719854693. PMID 31177840 DOI: 10.1177/0963689719854693  0.303
2019 Batsaikhan B, Wang JY, Scerba MT, Tweedie D, Greig NH, Miller JP, Hoffer BJ, Lin CT, Wang JY. Post-Injury Neuroprotective Effects of the Thalidomide Analog 3,6'-Dithiothalidomide on Traumatic Brain Injury. International Journal of Molecular Sciences. 20. PMID 30682785 DOI: 10.3390/ijms20030502  0.302
2018 Bader M, Li Y, Lecca D, Rubovitch V, Tweedie D, Glotfelty E, Rachmany L, Kim HK, Choi HI, Hoffer BJ, Pick CG, Greig NH, Kim DS. Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury. Neurobiology of Disease. PMID 30471415 DOI: 10.1016/J.Nbd.2018.11.023  0.75
2018 Chen S, Yu SJ, Li Y, Lecca D, Glotfelty E, Kim HK, Choi HI, Hoffer BJ, Greig NH, Kim DS, Wang Y. Author Correction: Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease. Scientific Reports. 8: 13953. PMID 30209317 DOI: 10.1038/s41598-018-31455-w  0.708
2018 Chen S, Yu SJ, Li Y, Lecca D, Glotfelty E, Kim HK, Choi HI, Hoffer BJ, Greig NH, Kim DS, Wang Y. Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease. Scientific Reports. 8: 10722. PMID 30013201 DOI: 10.1038/S41598-018-28449-Z  0.724
2017 Becker RE, Kapogiannis D, Greig NH. Does traumatic brain injury hold the key to the Alzheimer's puzzle? Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 29245000 DOI: 10.1016/j.jalz.2017.11.007  0.31
2017 Kim DS, Choi HI, Wang Y, Luo Y, Hoffer BJ, Greig NH. A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway. Cell Transplantation. 26: 1560-1571. PMID 29113464 DOI: 10.1177/0963689717721234  0.35
2017 Hoffer BJ, Pick CG, Hoffer ME, Becker RE, Chiang YH, Greig NH. Repositioning drugs for traumatic brain injury - N-acetyl cysteine and Phenserine. Journal of Biomedical Science. 24: 71. PMID 28886718 DOI: 10.1186/s12929-017-0377-1  0.304
2017 Kim DS, Choi HI, Wang Y, Luo Y, Hoffer BJ, Greig NH. A New Treatment Strategy for Parkinson's Disease Through the Gut-Brain Axis: The Glucagon-like Peptide-1 Receptor Pathway. Cell Transplantation. PMID 28447569 DOI: 10.3727/096368917X695669  0.35
2017 Brix KA, Brody DL, Grimes JB, Yitzhak A, Agoston D, Aldag M, Armstrong R, Arun P, Audette M, Babcock D, Balaban C, Banton R, Bellgowan P, Borkholder D, Broglio S, ... ... Greig N, et al. Military Blast Exposure and Chronic Neurodegeneration: Summary of Working Groups and Expert Panel Findings and Recommendations Journal of Neurotrauma. 34. DOI: 10.1089/Neu.2017.5222  0.322
2016 Tamargo IA, Bader M, Li Y, Yu SJ, Wang Y, Talbot K, DiMarchi RD, Pick CG, Greig NH. Novel GLP-1R/GIPR co-agonist "twincretin" is neuroprotective in cell and rodent models of mild traumatic brain injury. Experimental Neurology. PMID 27845037 DOI: 10.1016/j.expneurol.2016.11.005  0.305
2016 Chiu CC, Liao YE, Yang LY, Wang JY, Tweedie D, Karnati HK, Greig NH, Wang JY. Neuroinflammation in animal models of traumatic brain injury. Journal of Neuroscience Methods. PMID 27382003 DOI: 10.1016/j.jneumeth.2016.06.018  0.307
2016 Wang JY, Huang YN, Chiu CC, Tweedie D, Luo W, Pick CG, Chou SY, Luo Y, Hoffer BJ, Greig NH, Wang JY. Pomalidomide mitigates neuronal loss, neuroinflammation, and behavioral impairments induced by traumatic brain injury in rat. Journal of Neuroinflammation. 13: 168. PMID 27353053 DOI: 10.1186/s12974-016-0631-6  0.301
2016 Tweedie D, Fukui K, Li Y, Yu QS, Barak S, Tamargo IA, Rubovitch V, Holloway HW, Lehrmann E, Wood WH, Zhang Y, Becker KG, Perez E, Van Praag H, Luo Y, ... ... Greig NH, et al. Cognitive Impairments Induced by Concussive Mild Traumatic Brain Injury in Mouse Are Ameliorated by Treatment with Phenserine via Multiple Non-Cholinergic and Cholinergic Mechanisms. Plos One. 11: e0156493. PMID 27254111 DOI: 10.1371/Journal.Pone.0156493  0.329
2015 Li Y, Bader M, Tamargo I, Rubovitch V, Tweedie D, Pick CG, Greig NH. Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice. Journal of Neurochemistry. 135: 1203-17. PMID 25982185 DOI: 10.1111/jnc.13169  0.329
2014 Greig NH, Tweedie D, Rachmany L, Li Y, Rubovitch V, Schreiber S, Chiang YH, Hoffer BJ, Miller J, Lahiri DK, Sambamurti K, Becker RE, Pick CG. Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 10: S62-75. PMID 24529527 DOI: 10.1016/J.Jalz.2013.12.011  0.307
2013 Eakin K, Li Y, Chiang YH, Hoffer BJ, Rosenheim H, Greig NH, Miller JP. Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats. Plos One. 8: e82016. PMID 24312624 DOI: 10.1371/journal.pone.0082016  0.332
2013 Tweedie D, Rachmany L, Rubovitch V, Lehrmann E, Zhang Y, Becker KG, Perez E, Miller J, Hoffer BJ, Greig NH, Pick CG. Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice. Experimental Neurology. 239: 170-82. PMID 23059457 DOI: 10.1016/J.Expneurol.2012.10.001  0.302
2013 Rachmany L, Tweedie D, Li Y, Rubovitch V, Holloway HW, Miller J, Hoffer BJ, Greig NH, Pick CG. Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice. Age (Dordrecht, Netherlands). 35: 1621-36. PMID 22892942 DOI: 10.1007/s11357-012-9464-0  0.353
2012 Ray B, Bailey J, Nelson P, Greig N, Lahiri D. P1-215: Rivastigmine promotes APP processing via α-secretase pathway: Studies from neuron culture and animal model to postmortem brain tissues and its implications in Alzheimer's disease (AD) Alzheimer's & Dementia. 8: P182-P183. DOI: 10.1016/J.Jalz.2012.05.494  0.355
2011 Baratz R, Tweedie D, Rubovitch V, Luo W, Yoon JS, Hoffer BJ, Greig NH, Pick CG. Tumor necrosis factor-α synthesis inhibitor, 3,6'-dithiothalidomide, reverses behavioral impairments induced by minimal traumatic brain injury in mice. Journal of Neurochemistry. 118: 1032-42. PMID 21740439 DOI: 10.1111/j.1471-4159.2011.07377.x  0.302
2009 Martin B, Golden E, Carlson OD, Pistell P, Zhou J, Kim W, Frank BP, Thomas S, Chadwick WA, Greig NH, Bates GP, Sathasivam K, Bernier M, Maudsley S, Mattson MP, et al. Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. Diabetes. 58: 318-28. PMID 18984744 DOI: 10.2337/Db08-0799  0.303
2004 Greig NH, Mattson MP, Perry T, Chan SL, Giordano T, Sambamurti K, Rogers JT, Ovadia H, Lahiri DK. New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists. Annals of the New York Academy of Sciences. 1035: 290-315. PMID 15681814 DOI: 10.1196/Annals.1332.018  0.305
2004 Lahiri DK, Bailey J, Alley G, Chen D, Sambamurti K, Greig N. O3-06-01 Effects of diverse cholinesterase inhibitors and memantine on the amyloid pathway and its implications in Alzheimer's disease Neurobiology of Aging. 25: S63-S64. DOI: 10.1016/S0197-4580(04)80214-8  0.309
2002 Rogers JT, Randall JD, Eder PS, Huang X, Bush AI, Tanzi RE, Venti A, Payton SM, Giordano T, Nagano S, Cahill CM, Moir R, Lahiri DK, Greig N, Sarang SS, et al. Alzheimer's disease drug discovery targeted to the APP mRNA 5'untranslated region. Journal of Molecular Neuroscience : Mn. 19: 77-82. PMID 12212798 DOI: 10.1007/S12031-002-0014-6  0.333
2000 Culmsee C, Zhu X, Greig N, Guo Z, Camandola S, Crump S, Zhao D, Mattson M. The P53 inhibitor pifithrin-α protects neurons in experimental models of Alzheimer's disease Neurobiology of Aging. 21: 44. DOI: 10.1016/S0197-4580(00)82874-2  0.334
1996 Ingram DK, Shimada A, Spangler EL, Ikari H, Hengemihle J, Kuo H, Greig N. Cognitive enhancement. New strategies for stimulating cholinergic, glutamatergic, and nitric oxide systems. Annals of the New York Academy of Sciences. 786: 348-361. PMID 8687034 DOI: 10.1111/J.1749-6632.1996.Tb39076.X  0.335
1984 Greig N, Newell D, Hellmann K. Short communication: Metrazol enhances brain penetration and therapeutic efficacy of some anticancer agents: implications for brain metastases Clinical & Experimental Metastasis. 2: 55-59. PMID 6543690 DOI: 10.1007/Bf00132306  0.327
1983 Greig N, Hellmann K. Enhanced cerebrovascular permeability by Metrazol: significance for brain metastases. Clinical & Experimental Metastasis. 1: 83-95. PMID 6085721 DOI: 10.1007/Bf00118475  0.322
Show low-probability matches.